

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
 File Information Unit
 Crystal Plaza Three, Room 1D01
 2021 South Clark Place
 Arlington, VA
 Telephone: (703) 308-2733

RECEIVED	
MAY 20 2004	
File Information Unit	

In re Application of

Application Number

07-566977

Filed

8-13-90

Paper No. 27

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____,

United States Patent Number 5681941, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Darlene Jones
 Signature
Darlene Jones
 Typed or printed name

5-20-04

Date

FOR PTO USE ONLY

RECEIVED	
Approved by: <u>SAS</u> (initials)	
MAY 20 2004	
Unit: _____	

File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

US005681941A

27

United States Patent [19]

Cook et al.

[11] Patent Number: **5,681,941**[45] Date of Patent: **Oct. 28, 1997**[54] **SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING**

[75] Inventors: Phillip Dan Cook; Muthiah Manoharan, both of Carlsbad; Kanda S. Ramasamy, Laguna Hills, all of Calif.

[73] Assignee: ISIS Pharmaceuticals, Inc., Carlsbad, Calif.

[21] Appl. No.: 189,792

[22] Filed: Feb. 1, 1994

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 489,358, Jan. 11, 1990, abandoned, and Ser. No. 566,977, Aug. 13, 1990, abandoned.

[51] Int. Cl. ⁶ C07H 21/00; C07H 19/16

[52] U.S. Cl. 536/23.1; 536/22.1; 536/25.3; 536/25.34; 536/26.26; 536/26.7; 544/264

[58] Field of Search 536/22.1, 23.1, 536/25.3, 25.34, 26.7, 26.26; 544/264

[56] **References Cited****U.S. PATENT DOCUMENTS**

3,666,856	5/1972	Elion et al.	424/180
3,758,684	9/1973	Elion et al.	424/180
3,919,193	11/1975	Mian et al.	260/211.5 R
4,048,307	9/1977	Yokota et al.	424/180
4,081,534	3/1978	Elion et al.	424/180
4,123,610	10/1978	Summerton et al.	536/25.3
4,230,698	10/1980	Bobek et al.	424/180
4,321,366	3/1982	Bobek et al.	536/55
4,369,181	1/1983	Miller et al.	424/180
4,381,344	4/1983	Rideout et al.	435/87
4,481,197	11/1984	Rideout et al.	424/180
4,567,254	1/1986	Kataoka et al.	536/27
4,751,221	6/1988	Watanabe et al.	514/46
4,751,292	6/1988	Fox	536/24
4,751,293	6/1988	Kataoka et al.	536/27
4,755,594	7/1988	Bridges et al.	536/26
5,378,825	1/1995	Cook et al.	536/25.34
5,459,255	10/1995	Cook et al.	536/27.13

FOREIGN PATENT DOCUMENTS

WO 91/10671 7/1991 WIPO.
WO 91/14436 10/1991 WIPO.

} DO
NOT
NEED

OTHER PUBLICATIONS

Harris, et al., "New Strategy for the Synthesis of Oligonucleotides Bearing Adducts at Exocyclic Amino Sites of Purine Nucleosides", *J. Am. Chem. Soc.*, 1991, 113, 4328-4329.

Johnson, et al., "Site-Specific Adduct Formation in Oligomeric DNA Using a New Protecting Group", *J. Am. Chem. Soc.*, 1992, 114, 4923-4924.

Lee, et al., "Syntheses of Polycyclic Aromatic Hydrocarbon-Nucleoside and Oligonucleotide Adducts Specifically Alkylated on the Amino Functions of Deoxyguanosine and Deoxyadenosine", *Tetrahedron Letters*, 1990, 31, 6773-6776.

Casale, et al., "Synthesis and Properties of an Oligodeoxy-nucleotide Containing a Polycyclic Aromatic Hydrocarbon Site Specifically Bound to the N² Amino Group of a 2'-Deoxyguanosine Residue", *J. Am. Chem. Soc.*, 1990, 112, 5264-5271.

Meyer, et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligonucleotides", *J. Am. Chem. Soc.*, 1989, 111, 8517-

Pecoc'h, et al., "Efficient Chemical Synthesis of Oligodeoxy-nucleotides Containing a True Abasic Site", *Tetrahedron Letters*, 1987, 32, No. 2, 207-210.

Dreyer, et al., "Sequence-specific cleavage of single-stranded DNA: Oligonucleotide-EDTA.Fe(II)", *Proc. Natl. Acad. Sci.*, 1985, 82, 968-972.

Lesnik, et al., "Oligodeoxynucleotides Containing 2'-O-Modified Adenosine: Synthesis and Effects on Stability of DNA:RNA Duplexes", *Biochemistry*, 1993, 32, 7832-7838.

Miller, et al., "A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression)", *Anti-Cancer Drug Design*, 1987, 2, 117-128.

Uhlmann, et al., "Antisense Oligonucleotides: A New Therapeutic Principle", *Am. Chemical Reviews*, 1990, 90, No. 4, 543-584.

Cook, "Medicinal chemistry of antisense oligonucleotides-future opportunities", *Anti-Cancer Drug Design*, 1991, 6, 585-607.

Please
Get

DO
NOT
NEED